Clinical Trials Browser

Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Phase 3 Recruiting

750 enrolled

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT02605421 2025-10-21

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

Phase 2 Recruiting

12 enrolled

CNS

Neuroblastoma

NCT05735717 2025-07-24

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Phase 2 Recruiting

70 enrolled

CNSClassical hematologyLymphoidOther hematologic neoplasm

Chromosome 7, monosomy, Anemia, Refractory, with Excess of Blasts, Chromosome Aberrations, Influenza, Human, Neurofibromatosis 1, Leukemia, Myeloid, Acute, beta-Thalassemia, Neoplasm, Residual, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT01704716 2020-10-23

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

Phase 3 Recruiting

3,300 enrolled

CNS

Neuroblastoma

Clinical Trials

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)